<DOC>
	<DOC>NCT01038674</DOC>
	<brief_summary>This trial is conducted in Europe. The aim of this clinical trial is to investigate the safety and tolerability of the drug Anti-IL-20 in subjects with rheumatoid arthritis.</brief_summary>
	<brief_title>Safety and Tolerability of Anti-IL-20 in Subjects With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<criteria>Informed consent obtained before any trialrelated activities A diagnosis of rheumatoid arthritis made at least 3 months prior to screening Active rheumatoid arthritis, characterised by a DAS28 equal or above 3.2 Methotrexate treatment (stable dose, equal or below 25 mg/week) for at least 4 weeks prior to study start (subjects receiving stable doses of oral corticosteroids, and/or nonsteroidal antiinflammatory drugs and/or acetaminophen and/or opioids according to prescribed recommended doses can be included) Male subjects and female subjects of nonchild bearing potential Body mass index (BMI) less than 18.5 or above 35.0 kg/m2 Subjects with chronic inflammatory autoimmune disease other than rheumatoid arthritis History of or current inflammatory joint disease other than rheumatoid arthritis Chronic or ongoing infectious disease requiring systemic antiinfectious treatment within 2 weeks prior to study start Past or current malignancy (as judged by the investigator) Clinically significant cardiac or cardiovascular disease Positive for human immunodeficiency virus (HIV), hepatitis or tuberculosis Blood donation or blood loss of more than 0.45L within 2 months prior to study start, or longer if required by local regulations Breastfeeding women</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>